Saturday Rounds: Week of September 19-25, 2026

The week’s most important signal was not a new platform claim but five-year, maintenance-free disease control after a single cilta-cel infusion in early-line relapsed or refractory multiple myeloma — and the broader pattern held across editing, RNA and cell therapy alike: capital and attention moved…